Ready to Improve Your Biomarker Intelligence?

TALK TO A BIOMARKER STRATEGIST

Increased Clinical Trial Speed, and Decreased Adverse Events, Primary Drivers in Personalized Medicine

by

Genetic Engineering News just published a report describing personalized medicine’s progress, and it includes the results of a survey of “hundreds of respondents derived from a broad geographic swath … and broad affiliations.”

A key finding from this survey is that personalized medicine is being driven primarily by improvements in drug development, namely speed of clinical trials and reduction of potential for adverse events. Regulatory pressure is the next biggest factor.

Download the report here.